安科生物(300009) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 399,906,893.39, reflecting a growth of 2.27% year-on-year[3] - Net profit attributable to shareholders was CNY 109,712,471.57, representing an increase of 8.12% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was CNY 105,272,549.66, up by 5.87% year-on-year[3] - Basic earnings per share for the period was CNY 0.1045, a rise of 2.75% compared to the previous year[3] - The weighted average return on equity was 4.17%, down by 1.60% from the previous year[3] - Total operating revenue for Q3 2019 was CNY 399,906,893.39, an increase of 2.0% compared to CNY 391,013,634.35 in the same period last year[29] - Net profit for Q3 2019 reached CNY 109,710,343.10, compared to CNY 102,272,366.28 in Q3 2018, representing a growth of approximately 7.0%[30] - The total profit for Q3 2019 was CNY 106,003,512.53, reflecting a 25.1% increase from CNY 84,797,784.44 in the same quarter last year[33] - The net profit for the period was CNY 218,845,177.01, compared to CNY 179,155,694.02 in the previous period, reflecting an increase of approximately 22.19%[39] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,246,178,452.09, an increase of 28.46% compared to the end of the previous year[3] - Current liabilities decreased to CNY 280,485,200.75 from CNY 434,255,159.75, a reduction of about 35.4%[23] - Non-current assets totaled CNY 1,895,453,513.66, compared to CNY 1,770,508,032.21, reflecting an increase of approximately 7.1%[24] - The company's total liabilities decreased to CNY 396,245,540.51 from CNY 515,859,790.24, a decline of about 23.1%[23] - The company's equity attributable to shareholders rose to CNY 2,764,283,235.24, up from CNY 1,920,325,638.68, marking a growth of around 43.9%[24] Cash Flow - The net cash flow from operating activities was CNY 134,198,488.03, a decrease of 18.30% year-on-year[3] - Cash flow from investing activities for the first nine months of 2019 decreased by 336.09% year-on-year, primarily due to significant cash outflows for purchasing bank wealth management products[15] - Cash flow from financing activities for the first nine months of 2019 significantly increased, mainly due to substantial funds raised from a private placement of shares[15] - The cash flow from operating activities was CNY 134,198,488.03, a decrease from CNY 164,264,675.03 in the previous period, representing a decline of approximately 18.30%[41] - The net cash flow from financing activities was 450,255,240.07 CNY, compared to -79,906,168.60 CNY in the previous period, indicating a substantial improvement[46] Research and Development - R&D expenses for the first nine months of 2019 increased by 65.08% year-on-year, driven by accelerated progress in various R&D projects and increased investment[14] - Research and development expenses for Q3 2019 were CNY 24,424,859.80, up from CNY 20,452,905.92, indicating a focus on innovation[29] - Research and development expenses increased to CNY 49,341,243.92 from CNY 32,288,291.49, marking a rise of about 53.00%[39] Investment and Financial Performance - Investment income for the first nine months of 2019 significantly decreased, primarily due to substantial losses from long-term equity investments accounted for using the equity method[15] - The company reported an investment loss of CNY 7,468,760.33 for the year-to-date period, compared to a loss of CNY 6,544,552.70 in the previous year[36] - The investment income reported was a loss of CNY 7,349,144.78, compared to a loss of CNY 1,896,813.24 in the previous period, indicating a worsening of investment performance[39] Shareholder Information - The top shareholder, Song Lihua, holds 26.52% of the shares, totaling 278,576,096 shares[6] - The company completed the second phase of its restricted stock incentive plan, with the third unlocking period occurring on September 19, 2019[16] Other Financial Metrics - The company did not classify any non-recurring gains and losses as recurring during the reporting period[5] - The company did not undergo an audit for the third quarter report[47]